stay updated

Khondrion is collaborating globally on its way to market

In July 2018 Khondrion was awarded €2.3M funding from the highly competitive EU Horizon 2020 SME instrument program to progress clinical development...

Khondrion features in new video from Catalyze-Group®

Khondrion granted Orphan Drug Designation for KH176 for the treatment of MIDD from European Commission

Khondrion granted Orphan Drug Designation for KH176 for the treatment of maternally inherited diabetes and deafness (MIDD) from European Commission...

Scientific publication in Cell Death & Disease

Results from collaborative preclinical research effort investigating Leigh disease patient cells published in Cell Death and Disease NIJMEGEN, the...

Publication of the KHENERGY study results

KHENERGY study provides first data on safety and efficacy of KH176 in patients with mitochondrial disease. Results from phase IIa study of innovative reduction-oxidation modulator published in Clinical Pharmacology and Therapeutics.

Khondrion awarded H2020 SME Instrument grant

Khondrion receives €2.3M funding from EU Horizon 2020 SME instrument phase 2 program.

EuroHealth Leaders Magazine interviewed Khondrion's CEO Jan Smeitink

Jan Smeitink: Serving the Mitochondrial Medicine Mission Embarking on the journey of biopharmaceutical innovation demands more than just...

Khondrion to participate in the 16th Annual Dutch Inborn Error Meeting and the United Mitochondrial Disease Foundation (UMDF) Bench to Bedside seminar

Khondrion to participate in the 16th Annual Dutch Inborn Error Meeting and the United Mitochondrial Disease Foundation (UMDF) Bench to Bedside...

2022 – A Year in Review

2022 – A Year in Review As 2022 draws to a close, Khondrion’s CEO Jan Smeitink reflects on the significant progress achieved by Khondrion in its...

Patient Perspective: A conversation with Kate Murray – CEO and President, MitoCanada

How did you first become involved with the mitochondrial disease community and MitoCanada? I joined MitoCanada at a very exciting time, two months...

Patient Perspective: A conversation with Sean Murray – CEO, The Mito Foundation

How did you first become involved with the mitochondrial disease community and what led you to the Mito Foundation? I first learnt of mitochondrial...

Interview with Tom Pulles, Chief Medical Officer at Khondrion

Tell us about your career before joining KhondrionI started my career as a physician in the Dutch Navy, 22 years ago, following the...